Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRIO DarioHealth	$0.72 +0.2%	$0.70	$0.50 ▼ $1.55	$31.97M	1.55	287,129 shs	150,756 shs
LUCD Lucid Diagnostics	$1.14 -3.4%	$1.25	$0.72 ▼ $1.80	$123.34M	1.23	690,396 shs	1.55 million shs
LUNG Pulmonx	$2.90 +9.4%	$3.05	$2.50 ▼ $9.37	$116.75M	0.45	312,552 shs	1.79 million shs
OBIO Orchestra BioMed	$2.92 -2.7%	$2.95	$2.37 ▼ $8.87	$111.87M	0.61	180,689 shs	112,083 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRIO DarioHealth	0.00%	+2.42%	+3.08%	-0.91%	-44.69%
LUCD Lucid Diagnostics	0.00%	+4.97%	-12.98%	-2.56%	+35.15%
LUNG Pulmonx	0.00%	+4.50%	-7.64%	-44.76%	-54.33%
OBIO Orchestra BioMed	0.00%	+0.86%	-7.59%	-2.01%	-62.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DRIO DarioHealth	1.9439 of 5 stars	3.3	0.0	2.9	0.8	1.3
LUCD Lucid Diagnostics	2.6223 of 5 stars	3.6	2.0	2.9	1.7	0.6
LUNG Pulmonx	3.4509 of 5 stars	3.3	5.0	2.1	3.3	0.6
OBIO Orchestra BioMed	3.1462 of 5 stars	3.6	5.0	2.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DRIO DarioHealth	2.67	Moderate Buy	$2.00	178.16% Upside
LUCD Lucid Diagnostics	3.20	Buy	$3.55	211.40% Upside
LUNG Pulmonx	2.63	Moderate Buy	$11.53	297.41% Upside
OBIO Orchestra BioMed	3.20	Buy	$14.20	386.30% Upside

Current Analyst Ratings Breakdown

Latest DRIO, LUNG, LUCD, and OBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.50 ➝ $7.75
5/22/2025	LUNG Pulmonx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.50 ➝ $4.15
5/19/2025	DRIO DarioHealth	Litchfield Hills Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00
5/15/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00
5/14/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
5/13/2025	OBIO Orchestra BioMed	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/5/2025	OBIO Orchestra BioMed	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $12.00
5/1/2025	LUNG Pulmonx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/1/2025	LUNG Pulmonx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$10.00 ➝ $9.00
5/1/2025	LUNG Pulmonx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/23/2025	OBIO Orchestra BioMed	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DRIO DarioHealth	$27.04M	1.18	N/A	N/A	$2.11 per share	0.34
LUCD Lucid Diagnostics	$4.35M	28.35	N/A	N/A	($0.78) per share	-1.46
LUNG Pulmonx	$87.47M	1.33	N/A	N/A	$2.17 per share	1.34
OBIO Orchestra BioMed	$2.64M	42.37	N/A	N/A	$0.87 per share	3.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DRIO DarioHealth	-$42.75M	-$0.56	N/A	N/A	N/A	-159.80%	-65.81%	-38.41%	8/6/2025 (Estimated)
LUCD Lucid Diagnostics	-$45.53M	-$1.34	N/A	N/A	N/A	-1,699.86%	N/A	-124.27%	8/11/2025 (Estimated)
LUNG Pulmonx	-$56.39M	-$1.44	N/A	N/A	N/A	-65.27%	-63.69%	-34.94%	7/30/2025 (Estimated)
OBIO Orchestra BioMed	-$61.02M	-$1.78	N/A	N/A	N/A	-2,297.85%	-189.26%	-93.76%	N/A

Latest DRIO, LUNG, LUCD, and OBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	LUNG Pulmonx	-$0.40	N/A	N/A	N/A	$23.46 million	N/A
5/14/2025	Q1 2025	DRIO DarioHealth	-$0.07	-$0.14	-$0.07	-$0.14	$7.48 million	$6.75 million
5/12/2025	Q1 2025	OBIO Orchestra BioMed	-$0.46	-$0.49	-$0.03	-$0.49	$0.39 million	$0.87 million
5/7/2025	Q1 2025	LUNG Pulmonx	-$0.37	-$0.36	+$0.01	-$0.36	$22.03 million	$22.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DRIO DarioHealth	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
LUNG Pulmonx	N/A	N/A	N/A	N/A	N/A
OBIO Orchestra BioMed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DRIO DarioHealth	0.26	2.01	1.77
LUCD Lucid Diagnostics	N/A	0.75	0.74
LUNG Pulmonx	0.38	4.97	4.29
OBIO Orchestra BioMed	0.85	3.35	3.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DRIO DarioHealth	33.39%
LUCD Lucid Diagnostics	74.01%
LUNG Pulmonx	91.04%
OBIO Orchestra BioMed	53.55%

Insider Ownership

Company	Insider Ownership
DRIO DarioHealth	11.20%
LUCD Lucid Diagnostics	6.80%
LUNG Pulmonx	6.80%
OBIO Orchestra BioMed	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DRIO DarioHealth	200	44.46 million	39.48 million	Optionable
LUCD Lucid Diagnostics	70	108.19 million	100.83 million	No Data
LUNG Pulmonx	250	40.26 million	37.52 million	Optionable
OBIO Orchestra BioMed	4	38.31 million	35.21 million	Not Optionable

DRIO, LUNG, LUCD, and OBIO Headlines

Recent News About These Companies

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Rating of "Buy" by Brokerages

July 12 at 3:32 AM | marketbeat.com

Orchestra BioMed (NASDAQ:OBIO) Trading Up 1.7% - Here's What Happened

July 10 at 3:54 AM | marketbeat.com

Hedge funds owners may take dramatic actions as Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) recent 14% drop adds to one-year losses

July 2, 2025 | finance.yahoo.com

Orchestra BioMed Confirms Director Elections and Auditor

June 24, 2025 | tipranks.com

Orchestra BioMed Highlights Potential of AVIM Therapy for Managing Hypertension in High-Risk Patients at CSI 2025 Meeting

June 20, 2025 | nasdaq.com

Orchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 Meeting

June 18, 2025 | msn.com

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025

June 18, 2025 | globenewswire.com

Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships

May 28, 2025 | seekingalpha.com

Orchestra BioMed Holdings - Breakthrough Device Designation Gives Speculative Optimism

May 14, 2025 | seekingalpha.com

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates

May 12, 2025 | zacks.com

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

May 12, 2025 | globenewswire.com

Orchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough Designation

May 11, 2025 | msn.com

Orchestra BioMed Expands Patent Portfolio with 10 New Patents for Hypertension Treatment, Totaling 120 Global Patents

May 9, 2025 | nasdaq.com

Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 19.92%

May 9, 2025 | aaii.comA

Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

May 8, 2025 | finance.yahoo.com

Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

May 7, 2025 | globenewswire.com

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

May 5, 2025 | zacks.com

Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment

May 1, 2025 | msn.com

Orchestra BioMed to Present at Jefferies Global Healthcare Conference

May 1, 2025 | msn.com

Why Orchestra BioMed Holdings, Inc.’s (OBIO) Stock Is Up 7.51%

May 1, 2025 | aaii.comA

FDA approves head-to-head trial of Orchestra BioMed’s balloon

April 30, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Southwest Airlines: Short Interest Plunges—Should You Buy?
By Gabriel Osorio-Mazilli | June 17, 2025
View Southwest Airlines: Short Interest Plunges—Should You Buy?

DRIO, LUNG, LUCD, and OBIO Company Descriptions

DarioHealth NASDAQ:DRIO

$0.72 +0.00 (+0.22%)

Closing price 07/11/2025 03:59 PM Eastern

Extended Trading

$0.70 -0.01 (-1.95%)

As of 07/11/2025 05:46 PM Eastern

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

Lucid Diagnostics NASDAQ:LUCD

$1.14 -0.04 (-3.39%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$1.14 +0.00 (+0.35%)

As of 07/11/2025 07:55 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Pulmonx NASDAQ:LUNG

$2.90 +0.25 (+9.43%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$2.94 +0.04 (+1.38%)

As of 07/11/2025 07:57 PM Eastern

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Orchestra BioMed NASDAQ:OBIO

$2.92 -0.08 (-2.67%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$2.94 +0.02 (+0.68%)

As of 07/11/2025 07:06 PM Eastern

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time